Precise evaluation of myocardial damage by cardiac MRI – QUIEROMR
| ISRCTN | ISRCTN14130025 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN14130025 |
| ClinicalTrials.gov (NCT) | Nil known |
| Clinical Trials Information System (CTIS) | Nil known |
| Protocol serial number | Nil known |
| Sponsor | Charité |
| Funder | Charité – Universitätsmedizin Berlin |
- Submission date
- 26/10/2020
- Registration date
- 08/12/2020
- Last edited
- 15/01/2021
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Plain English summary of protocol
Background and study aims
Nearly 20 years ago researchers proved that it is possible to detect subtle changes in the myocardium (heart muscle) using cardiac MRI (CMR). Many disorders affecting the heart lead to a replacement of normal cells by fibrous tissue. Using CMR this process can be seen by applying a contrast agent to detect so-called late gadolinium enhancement (LGE). This method is considered to be the reference method for the detection of myocardial scars. This method has two major drawbacks: it is highly operator dependent and subjective, on patients with reduced kidney function are often excluded from contrast-based scans. To tackle these obstacles parametric techniques have been developed to assess myocardial damage with quantitative markers (e.g. T1 and T2 values). Previous studies could show that these tissue markers have diagnostic, therapeutic and prognostic implications. At the moment a separate scan has to be performed for each marker, taking more time and making a complete coverage of the ventricle impossible. The aim of this study is to assess new parametric techniques that acquire more than one parameter at a time in various heart diseases. The researchers expect to precisely detect myocardial damage in a shorter time. The study is organized under the HORIZON2020 Project QUIERO (Quantitative Imaging Enables Reproducible Outcomes) EU Grant Nr. 18HLT05.
Who can participate?
Patients aged at least 18 with one of the following heart diseases: ischemic heart disease (acute, subacute and chronic stages), rheumatological disorders with cardiac involvement, aortic stenosis, hypertrophic cardiomyopathy. Healthy volunteers aged at least 18 without any heart, kidney, lung or systemic disorders
What does the study involve?
All patients receive one MRI scan. Patients will be scanned before and after contrast agent application similar to a routine CMR scan. Healthy volunteers will be scanned without the use of contrast agent. Participants also provide blood samples and an ECG is recorded before the MRI scan.
What are the benefits and risk of participating?
Healthy volunteers and patients will receive a short description of their heart function with or without the description of myocardial scars.
Where is the study run from?
Charité Universitätsmedizin Berlin (Germany)
When is the study starting and how long is it expected to run for?
February 2020 to May 2022
Who is funding the study?
Charité Universitätsmedizin Berlin (Germany)
Who is the main contact?
Prof. Jeanette Schulz-Menger
jeanette.schulz-menger@charite.de
Contact information
Scientific
Charité Universitätsmedizin Berlin
Campus Berlin Buch – ECRC
AG Kardiale MRT - Prof. Schulz-Menger
Lindenbergweg 80
Berlin
13125
Germany
| Phone | + 49 (0)30 450540611 |
|---|---|
| jan.groeschel@charite.de |
Study information
| Primary study design | Observational |
|---|---|
| Study design | Observational single-center cohort study |
| Secondary study design | Case-control study |
| Study type | Participant information sheet |
| Scientific title | Quantitative analysis of myocardial damage in patients with focal and diffuse fibrosis by applying novel parametric mapping techniques in cardiac magnetic resonance |
| Study acronym | QUIEROMR |
| Study objectives | 1. Multi-parametric sequences allow the precise quantification of myocardial damage. There is no clinically relevant difference regarding the detection of focal and diffuse fibrosis by native T1 values obtained by multi-parametric sequences in comparison to reference methods. 2. Multi-parametric sequences allow the precise quantification of myocardial edema. There is no clinically relevant difference regarding the detection of myocardial edema by T2 values obtained by multi-parametric sequences in comparison to reference methods. |
| Ethics approval(s) | Approved 30/09/2020, ethics committee of Charité University Medicine Berlin Campus Mitte (Charité Medical Faculty, Charité – Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, 10117 Berlin, Germany; +49 (0)30 450 517 222; ethikkommission@charite.de), ref: EA4/166/20 |
| Health condition(s) or problem(s) studied | Diffuse and focal fibrosis in patients with cardiovascular disorders |
| Intervention | Patients are scanned once to assess possible focal or diffuse fibrosis using quantitative imaging techniques in cardiac MRI. Blood analysis is carried out before the MRI scan to measure NTproBnP, high-sensitive Troponin T, hematocrit, glomerular filtration rate. Physical exam of the cardiovascular apparatus and an ECG are carried out before the MRI scan as well. |
| Intervention type | Device |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | |
| Primary outcome measure(s) |
Myocardial T1 and T2 times, measured using novel and reference parametric mapping techniques once during the CMR scan (single timepoint) |
| Key secondary outcome measure(s) |
1. Detection and size of myocardial fibrosis using late gadolinium enhancement techniques and extracellular volume (ECV) by applying CMR once (single timepoint) |
| Completion date | 31/05/2022 |
Eligibility
| Participant type(s) | Mixed |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 75 |
| Key inclusion criteria | 1. Signed consent 2. Age at least 18 years (no upper limit) 3. For patients: previously detected pathology on MRI including: ischemic heart disease (acute, subacute and chronic stages), rheumatological disorders with cardiac manifestations, aortic stenosis, hypertrophic cardiomyopathy 4. For healthy volunteers: absence of cardiac, pulmonary, renal or systemic disorders |
| Key exclusion criteria | 1. Any contraindication for MRI 2. Chronic renal failure (glomerular filtration rate <30ml/min) 3. Previous participation in this study 4. Known allergy against MRI contrast agent 5. Pregnancy |
| Date of first enrolment | 01/01/2021 |
| Date of final enrolment | 31/12/2021 |
Locations
Countries of recruitment
- Germany
Study participating centres
Berlin
13125
Germany
Berlin
13125
Germany
Berlin
13125
Germany
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not expected to be made available |
| IPD sharing plan | The datasets generated during and/or analysed during the current study are not expected to be made available due to data protection laws in Germany. However, upon request the methodology and dataset structure can be shared. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
| Study website | Study website | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
15/01/2021: The following changes were made to the trial record:
1. The public title was changed from 'Precise evaluation of myocardial damage by cardiac MRI' to 'Precise evaluation of myocardial damage by cardiac MRI – QUIEROMR'.
2. The trial website was added.
27/10/2020: Trial's existence confirmed by the ethics committee of Charité University Medicine Berlin Campus Mitte.
